No Role for Topical Adapalene in Hidradenitis Suppurativa
Topical adapalene has no established role in the treatment of hidradenitis suppurativa and is not recommended based on current North American guidelines and available evidence.
Evidence-Based Rationale
The most recent and authoritative North American clinical management guidelines for HS (2019,2025) provide comprehensive recommendations for topical therapies but make no mention of adapalene or any retinoid for HS treatment 1, 2. This absence is significant given these guidelines systematically reviewed and graded all available evidence for topical treatments.
Recommended Topical Therapies for HS
The guidelines specifically recommend:
- Topical clindamycin 1% - May reduce pustules (though not inflammatory nodules/abscesses) but carries high risk of bacterial resistance 1
- Resorcinol 15% cream - A keratolytic and antiseptic that reduces pain and abscess duration, though contact dermatitis is common 1
- Antibacterial washes (chlorhexidine, benzoyl peroxide, zinc pyrithione) - Supported by expert opinion 1
- Intralesional triamcinolone - For acute inflamed lesions 1
Why Adapalene Is Not Appropriate
Mechanistic mismatch: Adapalene is a topical retinoid designed for acne vulgaris, where it works by normalizing follicular keratinization and reducing comedone formation 3, 4. HS pathophysiology differs fundamentally—it involves follicular occlusion of apocrine gland-bearing areas with subsequent rupture and inflammatory response, not the comedonal pathology of acne 5, 6.
No clinical evidence: Despite systematic reviews of topical and intralesional therapies for HS 7, adapalene has never been studied or reported for this indication. The comprehensive 2024 systematic review examining topical treatments found evidence only for clindamycin, photodynamic therapy, botulinum toxin, glucocorticoids, and resorcinol—but not retinoids 7.
Safety concerns in HS: The FDA labeling warns against using adapalene on damaged skin (cuts, abrasions, eczema) 3. HS lesions are characterized by deep nodules, abscesses, draining sinuses, and often open wounds—precisely the type of damaged skin where adapalene should not be applied.
Clinical Bottom Line
Use the evidence-based topical therapies outlined in North American guidelines: topical clindamycin 1% for pustular disease (combined with benzoyl peroxide to reduce resistance), resorcinol 15% for keratolytic/antiseptic effects, antibacterial washes for general skin care, and intralesional steroids for acute inflammatory nodules 1. For mild-to-moderate HS, combine these with systemic tetracyclines as first-line therapy 1. Adapalene should be reserved for its FDA-approved indication of acne vulgaris, not repurposed for HS where it lacks both evidence and mechanistic rationale.